Design of a Multiplex Serum Proteome Assay to Monitor Biologic Drug Response in Rheumatoid Arthritis Patients

N Callan, A Butt, SR Pennington, C McGeough, P Gardiner, G Wright, AJ Bjourson, DS Gibson

Research output: Contribution to journalArticle

2 Downloads (Pure)

Abstract

Background/Purpose: Biologic drugs have revolutionised the treatment of Rheumatoid Arthritis (RA), however these therapies are expensive and exhibit a high non–response rate (30%). Currently there are no specific biological markers which distinguish non-response early after initiating treatment. The aim of this study was to identify serum protein levels which change when disease activity score is reduced by biologic drug treatment. These proteins may give mechanistic insight into molecular events after failed therapeutic intervention. Methods: Sera and disease activity scores (DAS28-ESR) were collected from n=25 RA patients at baseline and six months after anti-tumour necrosis factor alpha treatment. EULAR response criteria were used. Untargeted (unbiased) label free LC-MS/MS based proteomics was used initially to discover sera proteins differentially expressed at six months in responders and non-responders. Multiple reaction monitoring (MRM) assays were designed and tested on a triple quadrupole mass spectrometer. Results: Over 500 proteins were identified in each of the pooled serum samples using the untargeted label free LC-MS/MS approach. Statistical analysis of the data revealed a list of 155 proteins that were significantly differentially expressed between good and non-responders (p
Original languageEnglish
JournalArthritis and Rheumatology
Volume68
Issue numberSuppl
Publication statusPublished - 28 Sep 2016

Keywords

  • Proteomics
  • Biomarkers
  • mass spectrometry
  • arthritis
  • assay
  • biologics

Fingerprint Dive into the research topics of 'Design of a Multiplex Serum Proteome Assay to Monitor Biologic Drug Response in Rheumatoid Arthritis Patients'. Together they form a unique fingerprint.

Cite this